In addition to practicing patent law, Brendan has worked as a licensing and business development professional in the pharmaceutical and biotechnology industries over the last 15 years. In this capacity, he has successfully sourced new products, led due diligence and commercial evaluation teams, and negotiated and executed agreements in the US, Europe and Far East. Most recently, Brendan led business development activities at NPS Pharma, a Rare Disease company that was acquired by Shire for $5.2 B. Prior to NPS Pharma, Brendan was the Chief Business Officer of Arrowhead Research Corporation where he worked to establish a comprehensive and advanced portfolio of leading RNAi technology, assets and IP. Brendan’s pharmaceutical licensing experience was gained at Hoffman-La Roche Ltd., and Purdue Pharma L.P. where he directed in-licensing and out-licensing activities.
Brendan obtained his Bachelor of Science degree in Microbiology from Glasgow University, and was awarded a Ph.D. by the Institute of Virology in Glasgow, Scotland. He was a Postdoctoral Fellow at the Roche Institute of Molecular Biology. He has been a Visiting Professor in the School of Host Infection and Immunity at Liverpool University in the United Kingdom since 2008. Brendan earned his Juris Doctor degree from Seton Hall Law School in Newark, New Jersey.